Citadel Advisors
NRXP icon

Citadel Advisors’s NRX Pharmaceuticals NRXP Stock Holding History

Citadel Advisors’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52.6K Sell
24,700
-11,100
-31% -$22.4K ﹤0.01% 12386
2025
Q4 		$97K Buy
35,800
+2,900
+9% +$7.78K ﹤0.01% 11667
2025
Q3 		$109K Buy
+32,900
New +$94.2K ﹤0.01% 11791
2025
Q1 		– Sell
-19,600
Closed -$43.1K – 15250
2024
Q4 		$43.1K Sell
19,600
-15,700
-44% -$21.1K ﹤0.01% 12545
2024
Q3 		$59.7K Buy
35,300
+12,890
+58% +$26K ﹤0.01% 11713
2024
Q2 		$54.7K Buy
22,410
+19,320
+625% +$68.7K ﹤0.01% 11657
2024
Q1 		$14.6K Sell
3,090
-5,710
-65% -$26.3K ﹤0.01% 13232
2023
Q4 		$40.5K Sell
8,800
-560
-6% -$1.85K ﹤0.01% 11999
2023
Q3 		$24.3K Buy
9,360
+590
+7% +$1.96K ﹤0.01% 12462
2023
Q2 		$42.4K Sell
8,770
-60
-0.7% -$361 ﹤0.01% 12003
2023
Q1 		$58.2K Sell
8,830
-7,690
-47% -$77.9K ﹤0.01% 11963
2022
Q4 		$183K Sell
16,520
-3,080
-16% -$31K ﹤0.01% 10284
2022
Q3 		$145K Sell
19,600
-2,670
-12% -$18K ﹤0.01% 10741
2022
Q2 		$134K Sell
22,270
-6,810
-23% -$89.5K ﹤0.01% 11099
2022
Q1 		$712K Buy
29,080
+240
+0.8% +$7.81K ﹤0.01% 8523
2021
Q4 		$1.38M Buy
28,840
+25,260
+706% +$1.82M ﹤0.01% 7084
2021
Q3 		$332K Buy
+3,580
New +$466K ﹤0.01% 10845

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BFG
Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citadel Advisors's NRXP Position: Q3 2025 in Review

Citadel Advisors sold out of NRX Pharmaceuticals (NRXP) in Q3 2025, closing a stake of 92,361 shares — an estimated $264K sold.

Citadel Advisors first reported a position in NRXP in Q3 2021 and held it in 6 quarters. The position peaked at $1.25M in Q3 2021. 24 funds tracked by Wall St. Rank hold NRXP as of Q3 2025.

  • Citadel Advisors reported no remaining NRX Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 92,361 NRX Pharmaceuticals shares in Q3 2025, an estimated $264K.
  • Citadel Advisors first reported a position in NRX Pharmaceuticals in Q3 2021 and held it in 6 quarters.
  • Citadel Advisors's NRX Pharmaceuticals position peaked at $1.25M in Q3 2021.
  • 24 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.